Kouki Harasaki, Ph.D. is the Founding / Managing Partner at Bioluminescence Ventures. The firm is based in San Francisco with $477M in AUM and invests in transformational platform companies that are developing first-in-class or best-in-class for patients with life-threatening diseases. The portfolio includes GEMMABio, Cerevance, ReCode Therapeutics, Ensoma, Nido Biosciences, Surge Therapeutics, and Tessera. Dr. Harasaki has over 20 years of biomedical science experience working across major health systems, research institutes, biopharmaceutical corporations, technology companies, and venture capital firms. He has led over $600M in financing deals that have funded more than 25 therapeutics programs across stages (discovery to marketed), across therapeutic areas (CVM, Immunology, Oncology, Neuro/CNS), and across modalities (small molecules, biologics, genome editors, cell therapies). Prior to founding Bioluminescence Ventures, Dr. Harasaki was Managing Director at M12 / Microsoft Ventures, where he led Life Sciences investments and helped develop Microsoft corporate strategy in the field. Prior to M12, he was a senior Partner at Andreessen Horowitz (Bio Fund). Prior to his time in venture capital, Dr. Harasaki held executive roles in Drug Discovery, Animal Pharmacology, Strategy, Finance, and Business Development at Novartis AG and Baxalta. At Baxalta, he was responsible for developing and executing the Immunology/Oncology corporate strategy, building the majority of the company's pipeline and portfolio (14 assets) via BD transactions. Baxalta was acquired by Shire in 2016 for $32B, in what would become the largest M&A transaction in the global biopharmaceutical industry that year. PhD, Clinical Biochemistry, University of Cambridge (Wellcome Trust Fellow) MBA, Harvard Business School (Robert S. Kaplan Fellow) BA, Molecular & Cellular Biology, Cornell University